<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00988312</url>
  </required_header>
  <id_info>
    <org_study_id>MyelomVak</org_study_id>
    <nct_id>NCT00988312</nct_id>
  </id_info>
  <brief_title>Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma</brief_title>
  <official_title>Vaccination With Idiotype-KLH Loaded Dendritic Cells. A Phase I Study for Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Carl Gustav Carus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Carl Gustav Carus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune
      cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions
      every 4 weeks. The aim is to induce an immune reaction against the malignant myeloma cells in
      order to slow down or cure the disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specific T-cell proliferation/cytokine secretion</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of T cells</measure>
    <time_frame>pre and post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>monoclonal protein</measure>
    <time_frame>pre and post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasmacells in bone marrow</measure>
    <time_frame>pre and post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs</measure>
    <time_frame>pre and post vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Plasmocytoma</condition>
  <arm_group>
    <arm_group_label>s.c. vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine given subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>i.v. vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccines are given intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous idiotype-protein pulsed dendritic cells</intervention_name>
    <description>Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks</description>
    <arm_group_label>s.c. vaccination</arm_group_label>
    <arm_group_label>i.v. vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  multiple myeloma

          -  stage I (Salmon &amp; Durie)

          -  no cytoreductive pre-treatment

        Exclusion Criteria:

          -  myeloma stages II-III

          -  asecretory disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Gretzinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2009</study_first_posted>
  <last_update_submitted>October 1, 2009</last_update_submitted>
  <last_update_submitted_qc>October 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Susanne Gretzinger</name_title>
    <organization>University Hospital Carl Gustav Carus</organization>
  </responsible_party>
  <keyword>dendritic cells (DC)</keyword>
  <keyword>idiotype (Id)</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunoglobulin Idiotypes</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

